Arcus Biosciences (RCUS) Receivables - Net (2017 - 2025)

Arcus Biosciences' Receivables - Net history runs 8 years deep, the most recent figure standing at $3.0 million for Q1 2025.

• On a quarterly basis, Receivables - Net fell 98.68% year-over-year to $3.0 million in Q1 2025; TTM through Mar 2025 was $3.0 million, a 98.68% decrease from a year earlier, with the FY2024 full-year figure at $228.0 million, up 7500.0% from the prior year.
• Receivables - Net slipped to $3.0 million in Q1 2025 per RCUS's latest filing, from $228.0 million in the prior quarter.
• Across five years, Receivables - Net topped out at $228.0 million in Q1 2024 and bottomed at $3.0 million in Q3 2023.
• The 5-year median for Receivables - Net is $4.1 million (2021), against an average of $56.7 million.
• Across the five-year window, Receivables - Net surged 7500.0% in 2024 and plunged 98.68% in 2025, its largest moves.
• Year by year, Receivables - Net stood at $4.9 million in 2021, then retreated by 18.37% to $4.0 million in 2022, then decreased by 25.0% to $3.0 million in 2023, then jumped by 7500.0% to $228.0 million in 2024, then plunged by 98.68% to $3.0 million in 2025.
• Per Business Quant, the three latest RCUS Receivables - Net figures stand at $3.0 million (Q1 2025), $228.0 million (Q4 2024), and $228.0 million (Q3 2024).